Inverse association between cancer and neurodegenerative disease: review of the epidemiologic and biological evidence

Biogerontology

Volumn 15, Issue 6, 2014, Pages 547-557

  Driver, Jane A ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer s disease; Cancer; Epidemiology; Neurodegeneration; Parkinson s disease

Indexed keywords

PEPTIDYLPROLYL ISOMERASE PIN1; PROTEASOME; UBIQUITIN;

ALZHEIMER DISEASE; CANCER INCIDENCE; CANCER PATIENT; CANCER SURVIVOR; CELL METABOLISM; COMORBIDITY; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; EPIDEMIOLOGICAL DATA; HIGH RISK PATIENT; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; NERVE CELL; NERVE DEGENERATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; AGING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASMS; NEURODEGENERATIVE DISEASES; PATHOLOGY; RISK FACTOR;

AGING; ALZHEIMER DISEASE; EPIDEMIOLOGIC FACTORS; GENE EXPRESSION REGULATION; HUMANS; NEOPLASMS; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; RISK FACTORS;

EID: 84916941205     PISSN: 13895729     EISSN: 15736768     Source Type: Journal    
DOI: 10.1007/s10522-014-9523-2     Document Type: Review

References (79)

1. Ackman JB, Ramos RL, Sarkisian MR, Loturco JJ (2007) Citron kinase is required for postnatal neurogenesis in the hippocampus. Dev Neurosci 29:113–123. doi:10.1159/000096216
2. Aljada A, Mousa SA (2012) Metformin and neoplasia: Implications and indications. Pharmacol Ther 133:108–115. doi:10.1016/j.pharmthera.2011.09.004
3. Bajaj A, Driver JA, Schernhammer ES (2009) Parkinson’s disease and cancer risk: A systematic review and meta-analysis. Cancer Causes & Control. Accepted pending revisions
4. Bakkour A, Morris JC, Dickerson BC (2009) The cortical signature of prodromal AD: Regional thinning predicts mild AD dementia. Neurology 72:1048–1055. doi:10.1212/01.wnl.0000340981.97664.2f
5. Bao L, Sauter G, Sowadski J, Lu KP, Wang D (2004) Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol 164:1727–1737
6. Behrens MI, Lendon C, Roe CM (2009) A common biological mechanism in cancer and Alzheimer’s disease? Curr Alzheimer Res 6:196–204
7. Benedict C, Kern W, Schultes B, Born J, Hallschmid M (2008) Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. J Clin Endocrinol Metab 93:1339–1344. doi:10.1210/jc.2007-2606
8. Catala-Lopez F et al (2014) Inverse and direct cancer comorbidity in people with central nervous system disorders: A meta-analysis of cancer incidence in 577,013 participants of 50 observational studies. Psychother Psychosom 83:89–105. doi:10.1159/000356498
9. Corsellis J (1962) Mental illness and the ageing brain. Oxford University Press, London
10. Craft S et al (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch Neurol 69:29–38. doi:10.1001/archneurol.2011.233
11. Crawford LJ, Walker B, Irvine AE (2011) Proteasome inhibitors in cancer therapy. J Cell Commun Signal 5:101–110. doi:10.1007/s12079-011-0121-7
12. de la Monte SM (2009) Insulin resistance and Alzheimer’s disease. BMB Rep 42:475–481
13. de la Monte SM, Luong T, Neely TR, Robinson D, Wands JR. (2000) Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer’s disease laboratory investigation; a journal of technical methods and pathology 80:1323–1335
14. Demetrius LA, Driver J (2013) Alzheimer’s as a metabolic disease. Biogerontology 14:641–649. doi:10.1007/s10522-013-9479-7
15. Demetrius LA, Simon DK (2012) An inverse-warburg effect and the origin of Alzheimer’s disease. Biogerontology 13:583–594. doi:10.1007/s10522-012-9403-6
16. Demetrius LA, Simon DK (2014) The inverse association of cancer and Alzheimer’s disease: A bioenergetic mechanism. J R Soc Interface 10: 20130006. 10.1098/rsif.2013.0006
17. Devine MJ, Plun-Favreau H, Wood NW (2011) Parkinson’s disease and cancer: Two wars, one front. Nat Rev Cancer 11:812–823
18. Dickerson BC et al (2009) The cortical signature of Alzheimer’s disease: Regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 19:497–510. doi:10.1093/cercor/bhn113
19. Doshay LJ (1954) Problem situations in the treatment of paralysis agitans. JAMA 156:680–684
20. Drachman DA (2006) Aging of the brain, entropy, and Alzheimer disease. Neurology 67:1340–1352. doi:10.1212/01.wnl.0000240127.89601.83
21. Driver JA (2012) Understanding the link between cancer and neurodegeneration. J Geriatr Oncol 3:58–67
22. Driver JA et al (2011) Inverse association between cancer and Alzheimer’s disease: Results from the Framingham Study. BMJ (in press)
23. Driver JA, Lu KP (2010) Pin1: a new genetic link between Alzheimer’s disease, cancer and aging. Curr Aging Sci 3:158–165
24. Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G (2007a) Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson’s disease. Cancer Causes Control 18:705–711. doi:10.1007/s10552-007-9005-9
25. Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T (2007b) A prospective cohort study of cancer incidence following the diagnosis of Parkinson’s disease. Cancer Epidemiol Biomarkers Prev 16:1260–1265. doi:10.1158/1055-9965.EPI-07-0038
26. Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G (2008) Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology 70:1423–1430. doi:10.1212/01.wnl.0000310414.85144.ee
27. Elbaz A et al (2002) Nonfatal cancer preceding Parkinson’s disease: A case-control study. Epidemiology 13:157–164
28. Elbaz A et al (2005) Risk of cancer after the diagnosis of Parkinson’s disease: A historical cohort study. Mov Disord 20:719–725
29. Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ (2009) Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson’s disease: Record linkage studies. J Neurol Neurosurg Psychiatry 81:215–221. doi:10.1136/jnnp.2009.175463
30. Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ (2010) Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson’s disease: Record linkage studies. J Neurol Neurosurg Psychiatry 81:215–221. doi:10.1136/jnnp.2009.175463
31. Folch J et al (2012) Role of cell cycle re-entry in neurons: A common apoptotic mechanism of neuronal cell death. Neurotox Res 22:195–207. doi:10.1007/s12640-011-9277-4
32. Freedman DM, Wu J, Daugherty SE, Kuncl RW, Enewold LR, Pfeiffer RM (2014) The risk of amyotrophic lateral sclerosis after cancer in U.S. elderly adults: A population-based prospective study. International journal of cancer. doi:10.1002/ijc.28795
33. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol 52:276–284. doi:10.1002/ana.10277
34. Holohan KN, Lahiri DK, Schneider BP, Foroud T, Saykin AJ (2012) Functional microRNAs in Alzheimer’s disease and cancer: differential regulation of common mechanisms and pathways Frontiers in genetics 3:323. doi:10.3389/fgene.2012.00323
35. Huang L, Chen CH (2009) Proteasome regulators: Activators and inhibitors. Curr Med Chem 16:931–939
36. Huang WK, Chiou MJ, Kuo CF, Lin YC, Yu KH, See LC (2014) No overall increased risk of cancer in patients with rheumatoid arthritis: A nationwide dynamic cohort study in Taiwan. Rheumatol Int. doi:10.1007/s00296-014-2982-6
37. Ibanez K, Boullosa C, Tabares-Seisdedos R, Baudot A, Valencia A (2014) Molecular evidence for the inverse comorbidity between central nervous system disorders and cancers detected by transcriptomic meta-analyses. PLoS Genet 10:e1004173. doi:10.1371/journal.pgen.1004173
38. Inestrosa NC, Toledo EM (2008) The role of Wnt signaling in neuronal dysfunction in Alzheimer’s disease. Mol Neurodegener 3:9. doi:10.1186/1750-1326-3-9
39. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG (2010) Metformin: Taking away the candy for cancer? Eur J Cancer 46:2369–2380. doi:10.1016/j.ejca.2010.06.012
40. Katsiki M, Chondrogianni N, Chinou I, Rivett AJ, Gonos ES (2007) The olive constituent oleuropein exhibits proteasome stimulatory properties in vitro and confers life span extension of human embryonic fibroblasts. Rejuvenation Res 10:157–172. doi:10.1089/rej.2006.0513
41. Kwak MK, Wakabayashi N, Greenlaw JL, Yamamoto M, Kensler TW (2003) Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol Cell Biol 23:8786–8794
42. Lombardi VR, Garcia M, Rey L, Cacabelos R (1999) Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer’s disease (AD) individuals. J Neuroimmunol 97:163–171
43. Lu KP, Zhou XZ (2007) The prolyl isomerase PIN1: A pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol 8:904–916. doi:10.1038/nrm2261
44. Lu J et al (2009) A novel functional variant (−842G > C) in the PIN1 promoter contributes to decreased risk of squamous cell carcinoma of the head and neck by diminishing the promoter activity. Carcinogenesis 30:1717–1721. doi:10.1093/carcin/bgp171
45. Manczak M, Park BS, Jung Y, Reddy PH (2004) Differential expression of oxidative phosphorylation genes in patients with Alzheimer’s disease: Implications for early mitochondrial dysfunction and oxidative damage. Neuromol Med 5:147–162. doi:10.1385/NMM:5:2:147
46. Marambaud P, Zhao H, Davies P (2005) Resveratrol promotes clearance of Alzheimer’s disease amyloid-beta peptides. J Biol Chem 280:37377–37382. doi:10.1074/jbc.M508246200
47. McNaught KS, Jnobaptiste R, Jackson T, Jengelley TA (2010) The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson’s disease. Synapse 64:241–250. doi:10.1002/syn.20719
48. Musicco M et al (2013) Inverse occurrence of cancer and Alzheimer disease: A population-based incidence study. Neurology 81:322–328. doi:10.1212/WNL.0b013e31829c5ec1
49. Nagy Z, Esiri MM, LeGris M, Matthews PM (1999) Mitochondrial enzyme expression in the hippocampus in relation to Alzheimer-type pathology. Acta Neuropathol 97:346–354
50. Noto H, Goto A, Tsujimoto T, Noda M (2012) Cancer risk in diabetic patients treated with metformin: A systematic review and meta-analysis. PLoS One 7:e33411. doi:10.1371/journal.pone.0033411
51. Nunomura A et al (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60:759–767
52. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H (2005) Atypical cancer pattern in patients with Parkinson’s disease. Br J Cancer 92:201–205
53. Olsen JH, Friis S, Frederiksen K (2006) Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 17:582–587
54. Paisan-Ruiz C, Houlden H (2010) Common pathogenic pathways in melanoma and Parkinson disease. Neurology 75:1653–1655. doi:10.1212/WNL.0b013e3181fb4466
55. Plun-Favreau H, Lewis PA, Hardy J, Martins LM, Wood NW (2010) Cancer and neurodegeneration: between the devil and the deep blue sea PLOS. Genetics 6:1–8
56. Raina AK, Zhu X, Rottkamp CA, Monteiro M, Takeda A, Smith MA (2000) Cyclin’ toward dementia: cell cycle abnormalities and abortive oncogenesis in Alzheimer disease. J Neurosci Res 61:128–133. doi:10.1002/1097-4547(20000715)61:2<128:AID-JNR2>3.0.CO;2-H
57. Roe CM, Behrens MI, Xiong C, Miller JP, Morris JC (2005) Alzheimer disease and cancer. Neurology 64:895–898
58. Roe CM et al (2010) Cancer linked to Alzheimer disease but not vascular dementia. Neurology 74:106–112. doi:10.1212/WNL.0b013e3181c91873
59. Rugbjerg K, Friis S, Lassen CF, Ritz B, Olsen JH (2012) Malignant melanoma, breast cancer and other cancers in patients with Parkinson’s disease. Int J Cancer 131:1904–1911. doi:10.1002/ijc.27443
60. Segat L et al (2007) PIN1 promoter polymorphisms are associated with Alzheimer’s disease. Neurobiol Aging 28:69–74. doi:10.1016/j.neurobiolaging.2005.11.009
61. Seo H, Sonntag KC, Kim W, Cattaneo E, Isacson O (2007) Proteasome activator enhances survival of Huntington’s disease neuronal model cells. PLoS One 2:e238. doi:10.1371/journal.pone.0000238
62. Shemesh E, Rudich A, Harman-Boehm I, Cukierman-Yaffe T (2012) Effect of intranasal insulin on cognitive function: A systematic review. J Clin Endocrinol Metab 97:366–376. doi:10.1210/jc.2011-1802
63. Sherman MY, Goldberg AL (2001) Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases. Neuron 29:15–32
64. Sorensen SA, Fenger K, Olsen JH (1999) Significantly lower incidence of cancer among patients with Huntington disease: An apoptotic effect of an expanded polyglutamine tract? Cancer 86:1342–1346
65. Staropoli JF (2008) Tumorigenesis and neurodegeneration: Two sides of the same coin? BioEssays 30:719–727. doi:10.1002/bies.20784
66. Stobart JL, Anderson CM (2013) Multifunctional role of astrocytes as gatekeepers of neuronal energy supply. Front Cell Neurosci 7:38. doi:10.3389/fncel.2013.00038
67. Tabares-Seisdedos R, Rubenstein JL (2013) Inverse cancer comorbidity: A serendipitous opportunity to gain insight into CNS disorders nature reviews. Neuroscience 14:293–304. doi:10.1038/nrn3464
68. Tabares-Seisdedos R et al (2011) No paradox, no progress: Inverse cancer comorbidity in people with other complex diseases. Lancet Oncol 12:604–608. doi:10.1016/S1470-2045(11)70041-9
69. Tacutu R, Budovsky A, Fraifeld VE (2010) The NetAge database: A compendium of networks for longevity, age-related diseases and associated processes. Biogerentology 11:513–522
70. Tirumalasetti F, Han L, Birkett DP (1991) The relationship between cancer and Alzheimer’s disease. J Am Geriatr Soc 39:840
71. van Heemst D et al (2005) Variation in the human TP53 gene affects old age survival and cancer mortality. Exp Gerontol 40:11–15
72. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324:1029–1033. doi:10.1126/science.1160809
73. Whitmer RA, Queensberry C, J. A. Karter AJ (2013) Anti-hyperglycemic therapy and risk of dementia: A new user cohort study. Alzheimer’s Dementia 9:136
74. Wolfson M, Budovsky A, Tacutu R, Fraifeld VE (2009) The signaling hubs at the crossroad of longevity and age-related disease networks. Int J Biochem Cell Biology 41:516–520
75. Xiang Z et al (2002) Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer’s disease neuropathology. Neurobiol Aging 23:327–334
76. Yaffe MB et al (1997) Sequence-specific and phosphorylation-dependent proline isomerization: A potential mitotic regulatory mechanism. Science 278:1957–1960
77. Yamada M et al (1999) Prevalence and risks of dementia in the Japanese population: RERF’s adult health study Hiroshima subjects. Radiation effects research foundation. J Am Geriatr Soc 47:189–195
78. Zheng B et al. (2010) PGC-1alpha, a potential therapeutic target for early intervention in Parkinson’s disease Science translational medicine 2:52ra73 doi:10.1126/scitranslmed.3001059
79. Zhu X, Lee HG, Perry G, Smith MA (2007) Alzheimer disease, the two-hit hypothesis: An update. Biochim Biophys Acta 1772:494–502. doi:10.1016/j.bbadis.2006.10.014